These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 5125856)
1. The labeling in vivo of monoamine oxidase by 14 C-pargyline: a tool for studying the synthesis of the enzyme. Erwin VG; Deitrich RA Mol Pharmacol; 1971 Mar; 7(2):219-28. PubMed ID: 5125856 [No Abstract] [Full Text] [Related]
2. Some considerations in the design of substrate and tissue-specific inhibitors of monoamine oxidase. Martin YC; Biel JH Adv Biochem Psychopharmacol; 1974; 12(0):37-48. PubMed ID: 4417042 [No Abstract] [Full Text] [Related]
3. [Kinetics, intracellular localization and inducibility of monoamine oxidase]. Zubrzycki Z; Staudinger H Hoppe Seylers Z Physiol Chem; 1967 Jun; 348(6):639-44. PubMed ID: 5601644 [No Abstract] [Full Text] [Related]
4. Rates of recovery of irreversibly inhibited monoamine oxidases: a measure of enzyme protein turnover. Planz G; Quiring K; Palm D Naunyn Schmiedebergs Arch Pharmacol; 1972; 273(1):27-42. PubMed ID: 4260803 [No Abstract] [Full Text] [Related]
5. Different sensitivity of mitochondrial and cytosolic monoamine oxidases to in vivo but not in vitro inhibition by specific irreversible inhibitors. Moskvitina TA; Medvedev AE Med Sci Monit; 2001; 7(1):17-9. PubMed ID: 11208486 [TBL] [Abstract][Full Text] [Related]
6. The binding of [3H] pargyline to rat liver mitochondrial monoamine oxidase. Parkinson D; Callingham BA J Pharm Pharmacol; 1980 Jan; 32(1):49-54. PubMed ID: 6102127 [TBL] [Abstract][Full Text] [Related]
7. Determination of monoamine oxidase concentrations in rat liver by inhibitor binding. Gomez N; Unzeta M; Tipton KF; Anderson MC; O'Carroll AM Biochem Pharmacol; 1986 Dec; 35(24):4467-72. PubMed ID: 3790166 [TBL] [Abstract][Full Text] [Related]
8. Electrophoretic characterization of monoamine oxidase by [3H]pargyline binding in rat hepatoma cells with A and B activity. Costa MR; Breakefield XO Mol Pharmacol; 1979 Jul; 16(1):242-9. PubMed ID: 481420 [No Abstract] [Full Text] [Related]
9. Spontaneous peripheral leakage of pargyline on intracerebroventricular administration. Ali B; Parmar SS; Seth PK; Brumleve SJ Res Commun Chem Pathol Pharmacol; 1973 Nov; 6(3):1083-6. PubMed ID: 4760882 [No Abstract] [Full Text] [Related]
10. Physicochemical properties, development, and regulation of central and peripheral monoamine oxidase activity. Youdim MB; Holzbauer M; Woods HF Adv Biochem Psychopharmacol; 1974; 12(0):11-28. PubMed ID: 4608303 [No Abstract] [Full Text] [Related]
11. Turnover rates of monoamine oxidases: recovery of the irreversibly inhibited enzyme activity and the influence of isoproterenol. Planz G; Quiring K; Palm D Life Sci I; 1972 Feb; 11(3):147-60. PubMed ID: 4653196 [No Abstract] [Full Text] [Related]
16. [Synthesis of monoamine oxidase in subcellular structures in normal conditions and in alcoholism]. Moskvitina TA Biomed Khim; 2006; 52(2):169-73. PubMed ID: 16805388 [TBL] [Abstract][Full Text] [Related]
17. [On the mechanism of inhibitory activity of pargyline on mitochondrial monoamine oxidases]. Vina I; Gorkin VZ; Gridneva LI; Kliashtorin LB Biokhimiia; 1966; 31(2):282-90. PubMed ID: 5999925 [No Abstract] [Full Text] [Related]
18. The influence of age on the recovery of cardiac monoamine oxidase after irreversible inhibition. Horita A Biochem Pharmacol; 1968 Oct; 17(10):2091-6. PubMed ID: 5696878 [No Abstract] [Full Text] [Related]
20. The turnover of the A- and B-forms of monoamine oxidase in rat liver. Corte LD; Tipton KF Biochem Pharmacol; 1980 Mar; 29(6):891-5. PubMed ID: 7387706 [No Abstract] [Full Text] [Related] [Next] [New Search]